Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | JAK1 | P23458 | 1/20 | 0.50 |
| ▸ | TYK2 | P29597 | 1/20 | 0.50 |
| ▸ | JAK3 | P52333 | 1/20 | 0.50 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA7 | P43166 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1043248 | 0.92 | L3MBTL1 (0.54) | LMNARAB9ANPC1KDM4EMAPT | |
| SCHEMBL12380464 | 0.86 | HCAR3 (0.60) | LMNACYP1A2CYP3A4MAOARAB9A | |
| SCHEMBL30096977 | 0.85 | LMNA (0.56) | LMNACYP1A2CYP3A4RAB9ANPC1 | |
| SCHEMBL24101021 | 0.84 | HCAR3 (0.67) | LMNACYP1A2CYP3A4MAOARAB9A | |
| SCHEMBL15258755 | 0.84 | GAA (0.44) | RAB9ANPC1KDM4EMAPTJAK2 | |
| SCHEMBL13739418 | 0.83 | MAPK1 (0.61) | RAB9ANPC1KDM4EMAPTCA1 | |
| SCHEMBL2861330 | 0.82 | RAB9A (0.58) | LMNACYP1A2CYP3A4MAOARAB9A | |
| SCHEMBL1345024 | 0.82 | HCAR3 (0.54) | LMNACYP1A2CYP3A4MAOARAB9A | |
| SCHEMBL16076748 | 0.81 | HPGD (0.62) | LMNACYP1A2CYP3A4MAOARAB9A | |
| SCHEMBL1542815 | 0.81 | HCAR3 (0.61) | RAB9ANPC1KDM4EMAPTJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4141977-A | Treatment of psoriasis with 6-substituted nicotinamides, 2-substituted pyrazinamides and closely related compounds | YU RUEY J | 1979-02-27 | — | — | US | claimed |
| CN-119823097-A | PHD inhibitor compounds, compositions and uses | 阿克比治疗有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-115551845-B | PHD inhibitor compounds, compositions and uses | 阿克比治疗有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20230227426-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230227426-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230227426-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| EP-4121425-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | Akebia Therapeutics Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| CN-115551845-A | PHD inhibitor compounds, compositions and uses | 阿克比治疗有限公司 | 2022-12-30 | — | — | CN | disclosed |
| WO-2021188936-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021188936-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-20100035906-A1 | Dipyridyl-dihydropyrazolones and their use | BAYER HEALTHCARE AG (DE) | 2010-02-11 | — | — | US | disclosed |
| WO-2009137201-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS | CV THERAPEUTICS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090253738-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. | 2009-10-08 | — | — | US | disclosed |
| US-20090253738-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. | 2009-10-08 | — | — | US | disclosed |
| EP-2084151-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HAEMATOLOGICAL DISEASES | Bayer HealthCare AG (DE) | 2009-08-05 | — | — | EP | disclosed |
| EP-1877396-B1 | 4-(PYRIDIN-3-YL)-2-(PYRIDIN-2-YL)-1,2-DIHYDRO-3H-PYRAZOL-3-ONE DERIVATIVES AS SPECIFIC HIF-PROLYL-4-HYDROXYLASE INHIBITORS FOR TREATING CARDIOVASCULAR AND HAEMATOLOGICAL DISEASES | BAYER HEALTHCARE AG (DE) | 2009-02-18 | — | — | EP | disclosed |
| WO-2008067871-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HAEMATOLOGICAL DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-12 | — | — | WO | disclosed |
| EP-1877396-A1 | 4-(PYRIDIN-3-YL)-2-(PYRIDIN-2-YL)-1,2-DIHYDRO-3H-PYRAZOL-3-ONE DERIVATIVES AS SPECIFIC HIF-PROLYL-4-HYDROXYLASE INHIBITORS FOR TREATING CARDIOVASCULAR AND HAEMATOLOGICAL DISEASES | Bayer HealthCare AG (DE) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006114213-A1 | 4-(PYRIDIN-3-YL)-2-(PYRIDIN-2-YL)-1,2-DIHYDRO-3H-PYRAZOL-3-ONE DERIVATIVES AS SPECIFIC HIF-PROLYL-4-HYDROXYLASE INHIBITORS FOR TREATING CARDIOVASCULAR AND HAEMATOLOGICAL DISEASES | BAYER HEALTHCARE AG (DE) | 2006-11-02 | — | — | WO | disclosed |
| US-4141977-A | Treatment of psoriasis with 6-substituted nicotinamides, 2-substituted pyrazinamides and closely related compounds | YU RUEY J | 1979-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035906-A1 | Dipyridyl-dihydropyrazolones and their use | DPP7, DPP4, QDPR | LMNA 3250/4885CYP1A2 2583/4885CYP3A4 2233/4885 |
| US-20230227426-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | HIF1AN, EGLN3, PHF20 | LMNA 4082/4885CYP1A2 2015/4885CYP3A4 3952/4885 |
| US-20090253738-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, FASN | LMNA 1654/4885CYP1A2 645/4885CYP3A4 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.